Month 6 on Tirzepatide: Halfway Through the First Year
Twenty-six weeks of treatment. Half a calendar year. By month 6 most users are at 10mg, deep into the productive phase of the loss curve, and well past the early-side-effect adjustment. The trajectory is no longer hypothetical.
By month 6, most users on the standard Zepbound titration schedule are at 10mg, having moved through 2.5mg, 5mg, 7.5mg, and 10mg in four-week blocks. Some are still at 7.5mg by choice, and a smaller group is already at 12.5mg ahead of schedule. Pace varies; the destination dose at this point is generally 10mg or above.
In SURMOUNT-1, the 10mg arm showed approximately 13–15% cumulative loss at month 6, with the 15mg arm slightly higher. Most users land somewhere in the 10–17% range at the six-month mark — a steeper average curve than semaglutide produces at the same checkpoint. Wide individual variation still applies; the average is a rough guide, not a target.
Appetite Suppression
Profound suppression at 10mg. Many users describe meals as functional rather than pleasurable in this phase; cravings are largely absent.
Mean cumulative loss at month 6 in SURMOUNT-1 active arms was approximately 13–15%, with the 15mg arm at the top of that range.
The Month 6 journey
The Month 6 Timeline
Weeks 21-22
Settled at 10mg
The dose feels routine. Side effects from the titration to 10mg have usually resolved by now, and the weekly rhythm is well established.
Weeks 23-24
Six-Month Review
Repeat labs are commonly scheduled here — A1C, lipids, liver enzymes, basic metabolic panel. Body composition changes are typically obvious in clothing and measurements by this point.
End of Month 6
Dose Decision
Move to 12.5mg, hold at 10mg, or continue lifestyle work while the dose stays steady. The right call depends on the trajectory, the side effect burden, and how much further you have to go.
What changes by Month 6
A half year of reduced intake has visibly reshaped the body. Many users report a drop in clothing sizes that no longer feels gradual — it is obvious week to week. Resting heart rate, blood pressure, and lab markers usually look meaningfully better than baseline. The metabolic story is often more impressive than the scale alone.
The first real plateau commonly appears in this window. A stretch of two to four weeks where the scale will not move, despite intake and routine staying constant, is a normal feature of the loss curve. Most users move through it without intervention. Sustained stalls beyond four weeks at the same dose are usually when a dose change, a habit audit, or a closer look at sleep and stress is worth considering.
Lean mass becomes a meaningful concern at this stage. Tirzepatide's faster average loss can pull more muscle if protein intake and resistance training are not part of the plan. Prescribers increasingly emphasize this at month 6: protein around 1.4–1.6g per kilogram of body weight per day, structured strength training twice a week, and attention to sleep and recovery.
Navigating Symptoms
Side effects at month 6 are usually well-controlled. Sustained low energy, hair shedding, or new mood changes are worth flagging — they can usually be addressed without stopping the medication.
What other users say
What Users Report
“Six months on 10mg, down 17%. Had a four-week stall around week 22 that I was sure meant the medication had stopped working. It hadn't — it just took its time.”
— Priya N.
“Halfway to my goal. My doctor and I agreed to stay at 10mg for now rather than rushing to 12.5mg. The dose is working and we want to leave room.”
— Marcus T.
Looking ahead
The second half of the first year is where the curve begins to flatten and the work becomes about consistency rather than progress. Continue to the Month 9 guide for what the late-year transition looks like, or revisit the resources hub for plateau strategies and dose questions.